Sort by
Items per page

Send to

Choose Destination

Links from Protein

Items: 1 to 20 of 135


Efficient growth suppression in pancreatic cancer PDX model by fully human anti-mesothelin CAR-T cells.

Jiang H, Song B, Wang P, Shi B, Li Q, Fan M, Di S, Yang J, Li Z.

Protein Cell. 2017 Dec;8(12):926-931. doi: 10.1007/s13238-017-0472-9. No abstract available.


Mesothelin promotes epithelial-to-mesenchymal transition and tumorigenicity of human lung cancer and mesothelioma cells.

He X, Wang L, Riedel H, Wang K, Yang Y, Dinu CZ, Rojanasakul Y.

Mol Cancer. 2017 Mar 14;16(1):63. doi: 10.1186/s12943-017-0633-8.


Correlation Between Tumor Mesothelin Expression and Serum Mesothelin in Patients with Epithelial Ovarian Carcinoma: A Potential Noninvasive Biomarker for Mesothelin-targeted Therapy.

Hanaoka T, Hasegawa K, Kato T, Sato S, Kurosaki A, Miyara A, Nagao S, Seki H, Yasuda M, Fujiwara K.

Mol Diagn Ther. 2017 Apr;21(2):187-198. doi: 10.1007/s40291-017-0255-2.


Role of mesothelin in carbon nanotube-induced carcinogenic transformation of human bronchial epithelial cells.

He X, Despeaux E, Stueckle TA, Chi A, Castranova V, Dinu CZ, Wang L, Rojanasakul Y.

Am J Physiol Lung Cell Mol Physiol. 2016 Sep 1;311(3):L538-49. doi: 10.1152/ajplung.00139.2016. Epub 2016 Jul 15.


Imaging the distribution of an antibody-drug conjugate constituent targeting mesothelin with ⁸⁹Zr and IRDye 800CW in mice bearing human pancreatic tumor xenografts.

ter Weele EJ, Terwisscha van Scheltinga AG, Kosterink JG, Pot L, Vedelaar SR, Lamberts LE, Williams SP, Lub-de Hooge MN, de Vries EG.

Oncotarget. 2015 Dec 8;6(39):42081-90. doi: 10.18632/oncotarget.5877.


Mesothelin (MSLN) methylation and soluble mesothelin-related protein levels in a Chinese asbestos-exposed population.

Yu M, Zhang Y, Jiang Z, Chen J, Liu L, Lou J, Zhang X.

Environ Health Prev Med. 2015 Sep;20(5):369-78. doi: 10.1007/s12199-015-0477-z. Epub 2015 Jul 19.


Functional genomic mRNA profiling of a large cancer data base demonstrates mesothelin overexpression in a broad range of tumor types.

Lamberts LE, de Groot DJ, Bense RD, de Vries EG, Fehrmann RS.

Oncotarget. 2015 Sep 29;6(29):28164-72. doi: 10.18632/oncotarget.4461.


Prognostic value of mesothelin expression in patients with triple negative and HER2-positive breast cancers.

Bayoglu IV, Kucukzeybek BB, Kucukzeybek Y, Varol U, Yildiz I, Alacacioglu A, Akyol M, Demir L, Dirican A, Yildiz Y, Salman T, Tarhan MO.

Biomed Pharmacother. 2015 Mar;70:190-5. doi: 10.1016/j.biopha.2015.01.019. Epub 2015 Jan 13.


Mesothelin expression in triple negative breast carcinomas correlates significantly with basal-like phenotype, distant metastases and decreased survival.

Tozbikian G, Brogi E, Kadota K, Catalano J, Akram M, Patil S, Ho AY, Reis-Filho JS, Weigelt B, Norton L, Adusumilli PS, Wen HY.

PLoS One. 2014 Dec 15;9(12):e114900. doi: 10.1371/journal.pone.0114900. eCollection 2014.


Pleural fluid mesothelin as an adjunct to the diagnosis of pleural malignant mesothelioma.

Creaney J, Segal A, Olsen N, Dick IM, Musk AW, Skates SJ, Robinson BW.

Dis Markers. 2014;2014:413946. doi: 10.1155/2014/413946. Epub 2014 Nov 23.


Preoperative serum levels of mesothelin in patients with colon cancer.

Bostancı O, Kemik O, Kemik A, Battal M, Demir U, Purisa S, Yavuz A, Mihmanlı M.

Dis Markers. 2014;2014:161954. doi: 10.1155/2014/161954. Epub 2014 Nov 13.


A common polymorphism within MSLN affects miR-611 binding site and soluble mesothelin levels in healthy people.

Garritano S, De Santi C, Silvestri R, Melaiu O, Cipollini M, Barone E, Lucchi M, Barale R, Mutti L, Gemignani F, Bonotti A, Foddis R, Cristaudo A, Landi S.

J Thorac Oncol. 2014 Nov;9(11):1662-8. doi: 10.1097/JTO.0000000000000322.


Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity.

Adusumilli PS, Cherkassky L, Villena-Vargas J, Colovos C, Servais E, Plotkin J, Jones DR, Sadelain M.

Sci Transl Med. 2014 Nov 5;6(261):261ra151. doi: 10.1126/scitranslmed.3010162.


A serum mesothelin level is a prognostic indicator for patients with malignant mesothelioma in routine clinical practice.

Linch M, Gennatas S, Kazikin S, Iqbal J, Gunapala R, Priest K, Severn J, Norton A, Ayite B, Bhosle J, O'Brien M, Popat S.

BMC Cancer. 2014 Sep 17;14:674. doi: 10.1186/1471-2407-14-674.


Mesothelin expression is associated with poor outcomes in breast cancer.

Li YR, Xian RR, Ziober A, Conejo-Garcia J, Perales-Puchalt A, June CH, Zhang PJ, Tchou J.

Breast Cancer Res Treat. 2014 Oct;147(3):675-84. doi: 10.1007/s10549-014-3077-5. Epub 2014 Sep 6.


Mesothelin expression in pancreatic mucinous cysts.

Frank R, Li S, Ahmad NA, Sepulveda AR, Jhala NC.

Am J Clin Pathol. 2014 Sep;142(3):313-9. doi: 10.1309/AJCPDTTL2I5ECMFG.


Discovery of mesothelin and exploiting it as a target for immunotherapy.

Pastan I, Hassan R.

Cancer Res. 2014 Jun 1;74(11):2907-12. doi: 10.1158/0008-5472.CAN-14-0337. Epub 2014 May 13. Review.


Expansion of anti-mesothelin specific CD4+ and CD8+ T cell responses in patients with pancreatic carcinoma.

Chen Y, Ayaru L, Mathew S, Morris E, Pereira SP, Behboudi S.

PLoS One. 2014 Feb 10;9(2):e88133. doi: 10.1371/journal.pone.0088133. eCollection 2014.


MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma.

Melaiu O, Stebbing J, Lombardo Y, Bracci E, Uehara N, Bonotti A, Cristaudo A, Foddis R, Mutti L, Barale R, Gemignani F, Giamas G, Landi S.

PLoS One. 2014 Jan 21;9(1):e85935. doi: 10.1371/journal.pone.0085935. eCollection 2014. Erratum in: PLoS One. 2017 Jun 22;12 (6):e0180317.


Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma.

Kachala SS, Bograd AJ, Villena-Vargas J, Suzuki K, Servais EL, Kadota K, Chou J, Sima CS, Vertes E, Rusch VW, Travis WD, Sadelain M, Adusumilli PS.

Clin Cancer Res. 2014 Feb 15;20(4):1020-8. doi: 10.1158/1078-0432.CCR-13-1862. Epub 2013 Dec 13. Erratum in: Clin Cancer Res. 2014 Jul 15;20(14):3896.

Supplemental Content

Support Center